Investment Thesis
Medpace demonstrates strong operational fundamentals with 20% revenue growth, robust 20% operating margins, and exceptional free cash flow generation ($145M, 20.5% of revenue). The company's zero debt, substantial cash reserves ($652.7M), and 20.7% ROE reflect financial strength, though net income growth stagnation despite revenue expansion and liquidity concerns warrant monitoring.
Strengths
- Strong revenue growth of 20% YoY demonstrates market demand and business momentum
- Exceptional free cash flow generation of $145M (20.5% FCF margin) with minimal capex requirements
- Zero long-term debt with $652.7M cash reserves providing financial flexibility and strategic optionality
- Excellent profitability with 20.0% operating margin and 17.5% net margin indicating operational efficiency
- High ROE of 20.7% demonstrates effective deployment of shareholder capital
Risks
- Current ratio of 0.85x indicates potential short-term liquidity constraint; current assets insufficient to cover current liabilities
- Net income growth of 0% YoY despite 20% revenue growth suggests margin compression or unfavorable operating leverage
- Divergence between strong FCF and flat net income raises questions about earnings quality and accrual management
- CRO sector cyclicality and client concentration risks typical of clinical research outsourcing business
- Insider activity of 12 Form 4 filings in 90 days warrants monitoring for insider confidence signals
Key Metrics to Watch
- Current ratio trajectory and working capital management - resolution of liquidity concern
- Operating margin sustainability with scale and revenue growth continuation
- Free cash flow conversion rate relative to net income to assess quality of earnings
- Client concentration and contract backlog trends to evaluate growth sustainability
- Capital allocation decisions and potential share repurchase activity driving EPS growth
Financial Metrics
Revenue
706.6M
Net Income
123.9M
EPS (Diluted)
$4.28
Free Cash Flow
145.0M
Total Assets
2.1B
Cash
652.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
20.0%
Net Margin
17.5%
ROE
20.7%
ROA
5.8%
FCF Margin
20.5%
Balance Sheet & Liquidity
Current Ratio
0.85x
Quick Ratio
0.85x
Debt/Equity
0.00x
Debt/Assets
71.9%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-29T14:07:33.183381 |
Data as of: 2026-03-31 |
Powered by Claude AI